High dose of Sanofi flu vaccine effective in trials

Sanofi's (SNY) influenza vaccine Fluzone High-Dose was 24.2% more effective in stopping people 65 years old and above from getting the flu than the standard dose of Fluzone in a large-scale trial.

With further testing still continuing, Sanofi expects to file a full clinical study to the FDA by early next year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs